Presentation is loading. Please wait.

Presentation is loading. Please wait.

Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,

Published byAmos Fowler Modified over 5 years ago

Similar presentations

Presentation on theme: "Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,"— Presentation transcript:

1 Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones, MD, Jacqueline A. Pongracic, MD, Ying Song, MD, Nan Yang, PhD, Scott H. Sicherer, MD, Melanie M. Makhija, MD, Rachel G. Robison, MD, Erin Moshier, MS, James Godbold, PhD, Hugh A. Sampson, MD, Xiu-Min Li, MD  Journal of Allergy and Clinical Immunology  Volume 136, Issue 4, Pages e1 (October 2015) DOI: /j.jaci Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Consort flow chart for this randomized, double-blind, placebo-controlled trial. After screening and baseline DBPCFCs with 2 g of protein, subjects were randomized to receive FAHF-2 or placebo (2:1), 10 tablets 3 times a day, for 6 months. After 6 months of treatment, a DBPCFC with 5 g of protein was performed to assess for the effect of the study medication. Subjects who demonstrated an improvement in tolerance (amount of food allergen that could be consumed without dose-limiting symptoms) as defined for the primary end point returned for a DBPCFC 3 months off therapy to assess for sustained effect. OFC, Oral food challenge. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Cumulative tolerated dose at oral food challenge (OFC) at baseline and after the 6-month treatment period comparing the active- and placebo-treated groups. The mean cumulative dose tolerated by the active group at baseline was 266.2 mg (95% CI,  mg), and at 6 months, the dose was 369.2 mg (95% CI,  mg). The mean cumulative dose tolerated by the placebo group at baseline was 352.5 mg (95% CI,  mg), and at 6 months, the dose was  mg (95% CI,  mg). Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 FAHF-2 suppressed IL-5 and increased IL-10 levels in vitro. A, PBMCs (4 × 105) from subjects (n = 12) were obtained at the baseline visit and cultured in AIM-V media alone, with relevant allergen (200 μg/mL) or allergen plus FAHF-2 (125 or 250 μg/mL). After a 3-day culture, culture supernatants were harvested, and IL-5, IFN-γ, and IL-10 levels were measured by means of ELISA. Cell viability was determined by using trypan blue dye exclusion. B, IL-5, IL-10, and IFN-γ production from PBMCs obtained at baseline with or without FAHF-2 in vitro culture (n = 53). Cultures were conducted as described in Fig 3, A. Data are shown as means ± SEMs and analyzed by using a left-censored, log-normal, repeated-measures tobit model. *P < .05, allergen versus allergen plus FAHF-2; ∗∗P < .01; and ∗∗∗P < .001. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 FAHF-2 increased numbers of Treg cells in vitro. PBMCs from subjects obtained at baseline were cultured as described in Fig 2. After a 3-day culture, numbers of CD4+CD25+FoxP3+ Treg cells were determined by means of flow cytometry. Data were analyzed by using FlowJo software. A, Dot plots are representative of an individual subject. B, Bar graph showing data for 10 subjects. Data are shown as means ± SEMs and analyzed by using a mixed model with a random intercept on natural log-transformed Treg cell percentages in Fig 3, B. *P < .05, allergen versus allergen plus FAHF-2. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,"

Similar presentations

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.
A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,
Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut  Claudia.

Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut  Claudia.
Immunotherapy for Food Allergy: Are We There Yet?

Immunotherapy for Food Allergy: Are We There Yet?
Corinne A. Keet, MD, MS, Pamela A

Corinne A. Keet, MD, MS, Pamela A
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,

Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,
Correlation of allergen-specific T follicular helper cell counts with specific IgE levels and efficacy of allergen immunotherapy  Yin Yao, MD, Cai-Ling.

Correlation of allergen-specific T follicular helper cell counts with specific IgE levels and efficacy of allergen immunotherapy  Yin Yao, MD, Cai-Ling.
Stacie M. Jones, MD, Scott H. Sicherer, MD, A

Stacie M. Jones, MD, Scott H. Sicherer, MD, A
Epigenetic regulation of established human type 1 versus type 2 cytokine responses  Ruey-Chyi Su, PhD, Allan B. Becker, MD, Anita L. Kozyrskyj, PhD, Kent.

Epigenetic regulation of established human type 1 versus type 2 cytokine responses  Ruey-Chyi Su, PhD, Allan B. Becker, MD, Anita L. Kozyrskyj, PhD, Kent.
Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy 

Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy 
Maternal allergy increases susceptibility to offspring allergy in association with TH2- biased epigenetic alterations in a mouse model of peanut allergy 

Maternal allergy increases susceptibility to offspring allergy in association with TH2- biased epigenetic alterations in a mouse model of peanut allergy 
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical.

Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical.
Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut  Claudia.

Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut  Claudia.
Toll-like receptor 7–induced naive human B-cell differentiation and immunoglobulin production  Mark C. Glaum, MD, PhD, Shilpi Narula, MD, Decheng Song,

Toll-like receptor 7–induced naive human B-cell differentiation and immunoglobulin production  Mark C. Glaum, MD, PhD, Shilpi Narula, MD, Decheng Song,
Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.
Targeting Toll-like receptors on dendritic cells modifies the TH2 response to peanut allergens in vitro  Pierre Pochard, PhD, Brian Vickery, MD, M. Cecilia.

Targeting Toll-like receptors on dendritic cells modifies the TH2 response to peanut allergens in vitro  Pierre Pochard, PhD, Brian Vickery, MD, M. Cecilia.
Julie Wang, MD, James H. Godbold, PhD, Hugh A. Sampson, MD 

Julie Wang, MD, James H. Godbold, PhD, Hugh A. Sampson, MD 
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Similar presentations

Ads by Google